Please login to the form below

US and Canada

This page shows the latest US and Canada news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: DDF hits £250m investment, Hard Brexit could cost UK £100bn in trade and troublesome results for Pfizer’s Ibrance

Business reps from the US, Canada, Japan and India issued a joint statement this week, which said that international businesses who are “heavily invested”in both the EU and the UK ... Canada Europe Roundtable for Business, the Europe India Chamber of

Latest news

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

In the US the situation is even more competitive, with all three drugs converging around second-line maintenance therapy. ... With the PARP inhibitors looking increasingly interchangeable from a clinical perspective, AZ enlisted the aid of MSD (known as
Maintenance OK boosts AstraZeneca’s Lynparza in Europe

In the US the situation is even more competitive, with all three drugs converging around second-line maintenance therapy. ... With the PARP inhibitors looking increasingly interchangeable from a clinical perspective, AZ enlisted the aid of MSD (known as
Sanofi’s latecomer PD-1 gets date for FDA verdict

The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... Priority review for Keytruda in NSCLC. Meanwhile,
Seattle Genetics claims key US approval for Adcetris

Seattle Genetics claims key US approval for Adcetris. Becomes the first new treatment for advanced Hl in more than 40 years. ... has rights to the drug outside the US and Canada.
$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

together. Merck (known as MSD outside the US and Canada) is paying $300m to Eisai - plus more than $5bn in potential milestones - to claim a share of the development and commercialisation ... buy-in and a commitment to studies of AZ’s drug alongside

More from news
Approximately 0 fully matching, plus 272 partially matching documents found.

Latest Intelligence

A unique ecosystem

Over 150 professionals from Europe and Canada attended the event, which brought together eight clusters with special focus on regenerative medicine - one of the focus areas of Medicen. ... In 2018, Medicen will continue its international dynamics with a
Deal Watch February 2017

In addition to the upfront and milestone payments, Immunomedics will receive tiered double digit royalties on global net sales, retains an option to co-promote IMMU-132 in the US and ... First approved in North America in 1989, Zoladex sales in 2016 were
2016: The year when deal-makers took stock?

Compounding this was the current political uncertainty following regime change in the US and Brexit, with the latter appearing to encourage caution in deal-making which may well continue into 2017. ... This has provided an opportunity for companies
Deal Watch October 2016

$4, 300 royalty. Buyout of collaboration. Respiratory 2015. Actavis US and Canada. ... The biosimilar market is heating up. This month Teva has entered into a US and Canada commercialisation arrangement with South Korea's Celltrion.
Deal Watch August 2016

A couple of studies in the US and Canada showed that hostile bids succeed in only 50% of cases. ... even assuming the clinical studies in the US and Europe meet all the target endpoints.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

NDA bolsters its senior team

US, Europe, Canada and other markets. ... Her contributions will help propel client strategy and accelerate programmes across the EU and US, as well as result in new intriguing service offerings that enable innovative companies to navigate the
Celgene’s president and COO to retire

Smith has over 30 years of business strategy experience across a range of therapeutic areas, having previously held senior leadership roles at Biovail in Canada, France, the US and Hong Kong, ... Smith's successor, Curran, joined Celgene in 2013 as the
Bayer appoints president of Americas pharma business

Bayer appoints president of Americas pharma business. Dr Carsten Brunn to lead operations across the US, Canada, Central and Latin America. ... Bayer has appointed Dr Carsten Brunn as the president of its pharmaceuticals business in the Americas,
Vikas Sinha joins Verona as non-executive director

Vikas Sinha joins Verona as non-executive director. Brings strong US and financial experience to the UK drug development firm. ... Prior to that he spent 11 years at Bayer, holding roles in the US, Canada, Japan and Germany, latterly as chief financial
Merck appoints new North America and China biopharma leaders

He will be responsible for the Massachusetts-based biopharma business' strategic direction and growth across the US and Canada. ... chief commercial officer for the US.

More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest from PMHub

Acute leukaemia patients get new online information centre that will help them get the best possible care

access to new treatments and clinical trials often depends on where they live. ... Most importantly, the panel of experts from the UK, Italy, France, Spain, Germany, Canada and the US provides insights into how to get the best from a healthcare team,
McCann Complete Medical Grows its Manchester Office

We are a growing employer in the UK and Manchester gives us a much needed additional footprint. ... McCann Complete Medical now has established offices in London, Oxford, Macclesfield, Manchester and Glasgow in the UK; New York, Hackensack, Chicago and
Acute leukaemia patients get new online information centre that will help them get the best possible care

Most importantly, the panel of experts from the UK, Italy, France, Spain, Germany, Canada and the US provides insights into how to get the best from a healthcare team, including what ... Follow us on Twitter: Like us on Facebook:
AXON Communications

AXON Communications. AXON, a global healthcare consulting firm, harnesses the diverse expertise of our talented team to help our clients create science-based strategies and drive stakeholder activation. ... AXON serves the healthcare communications needs
Only Medics

Authorities. We successfully recruit on both a contingent and retained basis on permanent positions as well as interim medical assignments. ... Our geographic reach is truly global and although our main focus is the European job market, we also recruit